Health and Fitness Health and Fitness
Tue, September 21, 2010
[ Tue, Sep 21st 2010 ] - Market Wire
Chemed Corporation to Present at JMP Securities Healthcare Conference
[ Tue, Sep 21st 2010 ] - Market Wire
Response Genetics, Inc. Sets New Date for 2010 Annual Meeting of Stockholders
[ Tue, Sep 21st 2010 ] - Market Wire
DIAGNOCURE';S PCA3 PROSTATE CANCER BIOMARKER SUBM .. EN-PROBE TO THE U.S. FOOD AND DRUG ADMINISTRATION
[ Tue, Sep 21st 2010 ] - Market Wire
Apricus Bio Receives FDA Guidance on Phase 3 Stud .. t for Raynauda?s Syndrome, Secondary to Scleroder
[ Tue, Sep 21st 2010 ] - Market Wire
Teva Files Complaint against Mylan for Infringement of Four Copaxone®-Related Patents
[ Tue, Sep 21st 2010 ] - Market Wire
Biogen Idec Announces Webcast of Hemophilia R&D Roundtable
[ Tue, Sep 21st 2010 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of Otix Global, Inc.
[ Tue, Sep 21st 2010 ] - Market Wire
Medical Facilities Corporation announces September distribution
[ Tue, Sep 21st 2010 ] - Market Wire
Extensin del programa mundial de estudios clnicos .. acuna contra el dengue de Sanofi Pasteur a Brasil
[ Tue, Sep 21st 2010 ] - Market Wire
IntraOp Medical Corporation Announces Purchase of .. in Southeast Asia by Siriraj Hospital in Thailand
[ Tue, Sep 21st 2010 ] - Market Wire
Miami Dolphins' Running Back Ricky Williams Joins .. w Healthy Living Products for Children and Adults
[ Tue, Sep 21st 2010 ] - Market Wire
Abiomed to Present at Lazard Capital Markets Circulatory Assist Device Day
[ Tue, Sep 21st 2010 ] - Market Wire
St. Jude Medical anuncia aprobacin europea de pro .. Athena para la gestin de tratamientos de estimula
[ Tue, Sep 21st 2010 ] - Market Wire
Roche's E-Plate VIEW Joins Impedance-based Real-time Monitoring with Visual Inspection of Cells
[ Tue, Sep 21st 2010 ] - Market Wire
St. Jude Medical Announces Results from Angio-Sea .. Vascular Closure Device Registry Subset Analysis
[ Tue, Sep 21st 2010 ] - Market Wire
Progenics Announces Clinical Completion of Subcut .. fety Study in Chronic Non-Malignant Pain Patients
[ Tue, Sep 21st 2010 ] - Market Wire
Exact Sciences to Present at JMP Securities Healthcare Conference
[ Tue, Sep 21st 2010 ] - Market Wire
Clinical Data, Inc. to Present at the JMP Securities Healthcare Conference
[ Tue, Sep 21st 2010 ] - Market Wire
Celera Announces Issuance of United States Patent .. nt as a Predictor of Increased Risk of Myocardial
[ Tue, Sep 21st 2010 ] - Market Wire
Salix Pharmaceuticals to Present at JMP Conference
[ Tue, Sep 21st 2010 ] - Market Wire
BioCryst to Present At JMP Securities Healthcare Conference
[ Tue, Sep 21st 2010 ] - Market Wire
ImmunoGen, Inc. Announces Start of SAR566658 Clinical Testing
[ Tue, Sep 21st 2010 ] - Market Wire
Cardiac Science Launches Cambridge Hearta?s Micro .. lternans (MTWA) Technology in Stress Test Systems
[ Tue, Sep 21st 2010 ] - Market Wire
DaVita Announces Refinancing of Existing Indebtedness and Estimate of Third Quarter Earnings
Mon, September 20, 2010
[ Mon, Sep 20th 2010 ] - Market Wire
LifePoint Hospitals, Inc. Announces Pricing of $400 Million of Its 6.625% Senior Notes
[ Mon, Sep 20th 2010 ] - Market Wire
Transcend Unveils BeyondAlertsa" to Provide Real-time Monitoring of Clinical Quality Measures
[ Mon, Sep 20th 2010 ] - Market Wire
Intuitive Surgical, Inc. Third Quarter 2010 Earnings Conference Call
[ Mon, Sep 20th 2010 ] - Market Wire
Somaxon Pharmaceuticals Appoints Faheem Hasnain to Its Board of Directors
[ Mon, Sep 20th 2010 ] - Market Wire
Philip Emond Named as CIGNAa?s Chief Information Officer
[ Mon, Sep 20th 2010 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the UBS Global Life Sciences Conference

Alkermesa? Corporate Presentation to be Webcast at the UBS Global Life Sciences Conference


Published on 2010-09-20 13:05:26 - Market Wire
  Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the UBS Life Sciences Conference on Wednesday, September 22, 2010, at 8:30 a.m. ET from the Grand Hyatt Hotel in New York. The presentation may be accessed under the investor relations tab at [ www.alkermes.com ]. The presentation will be archived for 14 days.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

Contributing Sources